# Phase I Clinical Trial of a COVID-19 Vaccine in 18-60 Healthy Adults

> **NCT04313127** · PHASE1 · COMPLETED · sponsor: **CanSino Biologics Inc.** · enrollment: 108 (actual)

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector)

## Key facts

- **NCT ID:** NCT04313127
- **Lead sponsor:** CanSino Biologics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-03-16
- **Primary completion:** 2021-01-20
- **Final completion:** 2021-02-20
- **Target enrollment:** 108 (ACTUAL)
- **Last updated:** 2021-08-04

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04313127

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04313127, "Phase I Clinical Trial of a COVID-19 Vaccine in 18-60 Healthy Adults". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04313127. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*